Cationic Proteins Inactivating Clostridium difficile Toxins
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Clostridium difficile infections, such as those caused by Toxin A and Toxin B, are inadequate due to high relapse and fatality rates, and there is a need for therapies that target the toxins rather than the pathogen, especially given the rise in severe and recurrent cases associated with hypervirulent strains.
Innovation Solution
The use of cationic proteins like protamine, protamine III-2 peptide, polyarginine, and polylysine to inactivate Clostridium difficile toxins, either by specific or non-specific binding, and leucine peptides to reduce toxin production, potentially combined with antibiotics or toxin production inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If antibiotics are used to treat C. difficile infection, then bacterial load is reduced, but toxin production continues and relapse occurs
Solution Approach 1:
The invention extracts and targets the toxin component separately from the bacteria. By using cationic proteins to bind and neutralize toxins in the gut lumen, the treatment addresses the harmful toxin production that persists even after antibiotic reduction of bacterial load, thereby improving treatment reliability and preventing relapse
Solution Approach 2:
Cationic proteins serve as intermediary agents between the toxin and the intestinal epithelium. These proteins bind to toxins through electrostatic interactions, forming neutral complexes that cannot penetrate cells, thereby preventing toxin-mediated damage while allowing the bacteria to be cleared by the immune system
2Object-affected harmful factors
If current antibiotic therapies are used, then bacterial infection is treated, but tissue and organ damage continues due to persistent toxin activity
Solution Approach 1:
The invention converts the harmful toxin molecules into beneficial neutral complexes. Cationic proteins bind to the toxic anionic molecules, transforming them from harmful pathogens into harmless complexes that are excreted, thereby eliminating tissue damage while preserving the body's natural immune response to clear the bacteria
3Ease of operation
If antibiotics alone are administered, then pathogen is targeted, but toxin neutralization is insufficient leading to high relapse rates
Solution Approach 1:
The invention creates a composite therapeutic approach combining antibiotics with cationic proteins. This composite strategy addresses both the bacterial pathogen and its toxin products simultaneously, improving reliability by preventing relapse through dual action while maintaining ease of operation through a single administered formulation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively inactivate or reduce the production of Clostridium difficile toxins, thereby ameliorating tissue and organ damage and potentially reducing the severity and recurrence of infections, offering a novel non-antimicrobial approach to managing Clostridium difficile infections.
Implementation Method 1
The data presented herein show the effects of various compounds that may inactivate Clostridium difficile toxin. For example, compounds having a high cationic surface charge may be useful to mediate this effect
Data Source
AI summary
The present invention is related to compositions and methods to treat, ameliorate and/or prevent morbidity and/or mortality from microbial infections. In particular, bacterial infections that are associated with the production and release of bacterial toxins. For example, many Clostridia bacteria, such as Clostridium difficile, release toxins resulting in tissue and organ damage and death, even after antibiotic therapy that either reduces or eliminates the bacteria. In particular, various peptides, polypeptides, and proteins are disclosed herein that either inactivate Clostridium difficile toxin and/or reduce Clostridium difficile toxin production.